



Kollidon® 12 PF / Kollidon® 17 PF

The endotoxin-controlled PVP-based solubilizers for parenteral and oral formulations

Did you know that Kollidon® 12 PF and Kollidon® 17 PF are highly suitable for injectable formulations? Kollidon® 12 PF/ Kollidon® 17 PF low molecular weight make them particularly suitable for parenteral applications. Additionally, they are used as matrix formers in solid dispersions, highly effective stabilizers in liquid dispersions, as well as functional pore formers in solid oral dosage forms.

- ✓ Highly soluble low molecular weight povidone
- ✓ Endotoxin-controlled
- ✓ Suitable as solubilizer and crystallization inhibitor
- ✓ PeroXeal™ packaging for minimizing peroxide formation



BASF
We create chemistry



Product Benefits

Formation of water-soluble complexes with APIs inhibits crystallization
Excellent lyophilization agents and suspension stabilizers
Rapid renal elimination without polymer accumulation in the body due to low molecular weight
Proven tolerability
Endotoxin-controlled

Complies to the Povidone monographs of Ph.Eur., USP-NF, and JP
FDA IID listed
Innovative PeroXeal™ packaging concept limiting peroxide formation – a unique combination of an oxygen impermeable inliner packaging and a filling process under inert conditions

Product Details

Brand/Trade name	Kollidon® 12 PF	Kollidon® 17 PF
Generic name	Povidon(e), polyvidone, soluble polyvinylpyrrolidone, PVP	
CAS number	9003-39-8	
PRD number	30034972	30034981
Packaging size	50 kg plastic drum with inliner	50 kg plastic drum with inliner
Article number	50444166	50029276
Manufacturing site	Ludwigshafen (Germany)	
Physical form	Powder	

Regulatory Documentation

A Certificate of Suitability of Monographs of the European Pharmacopoeia (CEP) is available (CEP-2007-077).

Pharmacopoeia Monographs and Titles

Kollidon® 12 PF and Kollidon® 17 PF meet the requirements of the current monograph “Povidone” in the European Pharmacopoeia, United States Pharmacopoeia, and Japanese Pharmacopoeia.

Preclinical Safety Data

Tox Abstract (summary of the design and results of the pre-clinical studies performed) is available.

i For further information on the preclinical safety data and our secrecy agreement please contact your sales representative.

Get your sample today!
pharma.basf.com/request-a-sample